178 related articles for article (PubMed ID: 33836682)
1. Correlations among disability, anti-AQP4 antibody status and prognosis in the spinal cord involved patients with NMOSD.
Hsu JL; Liao MF; Chang KH; Cheng MY; Ro LS
BMC Neurol; 2021 Apr; 21(1):153. PubMed ID: 33836682
[TBL] [Abstract][Full Text] [Related]
2. Whole spinal transverse myelitis in neuromyelitis optica spectrum disorder.
Etemadifar M; Mousavi S; Salari M; Hosseinian SA; Mansouri AR
Mult Scler Relat Disord; 2024 Jul; 87():105666. PubMed ID: 38749352
[TBL] [Abstract][Full Text] [Related]
3. Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD.
Duchow A; Bellmann-Strobl J; Friede T; Aktas O; Angstwurm K; Ayzenberg I; Berthele A; Dawin E; Engels D; Fischer K; Flaskamp M; Giglhuber K; Grothe M; Havla J; Hümmert MW; Jarius S; Kaste M; Kern P; Kleiter I; Klotz L; Korporal-Kuhnke M; Kraemer M; Krumbholz M; Kümpfel T; Lohmann L; Ringelstein M; Rommer P; Schindler P; Schubert C; Schwake C; Senel M; Then Bergh F; Tkachenko D; Tumani H; Trebst C; Vardakas I; Walter A; Warnke C; Weber MS; Wickel J; Wildemann B; Winkelmann A; Paul F; Stellmann JP; Häußler V;
Ann Neurol; 2024 Apr; 95(4):720-732. PubMed ID: 38086777
[TBL] [Abstract][Full Text] [Related]
4. Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.
Jurynczyk M; Probert F; Yeo T; Tackley G; Claridge TDW; Cavey A; Woodhall MR; Arora S; Winkler T; Schiffer E; Vincent A; DeLuca G; Sibson NR; Isabel Leite M; Waters P; Anthony DC; Palace J
Acta Neuropathol Commun; 2017 Dec; 5(1):95. PubMed ID: 29208041
[TBL] [Abstract][Full Text] [Related]
5. Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody-Associated Disease.
Cacciaguerra L; Abdel-Mannan O; Champsas D; Mankad K; Krecke KN; Chen JJ; Syc-Mazurek SB; Redenbaugh V; Lopez-Chiriboga AS; Valencia-Sanchez C; Hemingway C; Tillema JM; Ciccarelli O; Pittock SJ; Hacohen Y; Flanagan EP
Neurology; 2024 May; 102(10):e209303. PubMed ID: 38710000
[TBL] [Abstract][Full Text] [Related]
6. The absence of antibodies in longitudinally extensive transverse myelitis may predict a more favourable prognosis.
Rocchi C; Forcadela M; Kelly P; Linaker S; Gibbons E; Bhojak M; Jacob A; Hamid S; Huda S
Mult Scler; 2024 Mar; 30(3):345-356. PubMed ID: 38258822
[TBL] [Abstract][Full Text] [Related]
7. Brain and spinal cord atrophy in NMOSD and MOGAD: Current evidence and future perspectives.
Lorefice L; Cortese R
Mult Scler Relat Disord; 2024 May; 85():105559. PubMed ID: 38554671
[TBL] [Abstract][Full Text] [Related]
8. Discrepancy in clinical and laboratory profiles of NMOSD patients between AQP4 antibody positive and negative: can NMOSD be diagnosed without AQP4 antibody?
Chu F; Shi M; Liu C; Zhu J
Clin Exp Immunol; 2023 Oct; 213(3):363-370. PubMed ID: 37161978
[TBL] [Abstract][Full Text] [Related]
9. Comparison of efficacy of plasma exchange versus intravenous immunoglobulin as an add-on therapy in acute attacks of neuromyelitis optica spectrum disorder.
Siwach G; Hans R; Takkar A; Ahuja CK; Lamba DS; Lal V; Sharma RR
J Clin Apher; 2024 Jun; 39(3):e22129. PubMed ID: 38850074
[TBL] [Abstract][Full Text] [Related]
10. Serum Proteomics Distinguish Subtypes of NMO Spectrum Disorder and MOG Antibody-Associated Disease and Highlight Effects of B-Cell Depletion.
Gawde S; Siebert N; Ruprecht K; Kumar G; Ko RM; Massey K; Guthridge JM; Mao-Draayer Y; Schindler P; Hastermann M; Pardo G; Paul F; Axtell RC
Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200268. PubMed ID: 38885457
[TBL] [Abstract][Full Text] [Related]
11. A study of referral bias in NMOSD and MOGAD cohorts.
Leal Rato M; Chen B; Francis A; Messina S; Miron M; Sharawakanda Y; O'Sullivan E; Cooper S; Fisniku L; Halfpenny C; Martin R; Hobart J; Rashid W; Hemingway C; Williams V; Hacohen Y; Dobson R; Ramdas S; Leite MI; Palace J; Geraldes R
Mult Scler Relat Disord; 2024 May; 85():105553. PubMed ID: 38552551
[TBL] [Abstract][Full Text] [Related]
12. Impact of Autologous Mesenchymal Stem Cell Infusion on Neuromyelitis Optica Spectrum Disorder: A Pilot, 2-Year Observational Study.
Fu Y; Yan Y; Qi Y; Yang L; Li T; Zhang N; Yu C; Su L; Zhang R; Shen Y; Lin S; Liu Q; Shao Z; Han Z; Shi FD
CNS Neurosci Ther; 2016 Aug; 22(8):677-85. PubMed ID: 27219819
[TBL] [Abstract][Full Text] [Related]
13. Long-term disability progression in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a retrospective analysis of 101 patients.
Uzawa A; Mori M; Masuda H; Uchida T; Muto M; Ohtani R; Aoyama S; Kuwabara S
J Neurol Neurosurg Psychiatry; 2024 Jun; 95(7):626-629. PubMed ID: 38176896
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of patients with neuromyelitis optica spectrum disorder (NMOSD) combined with chronic hepatitis B (CHB) infection and seropositive for anti-aquaporin-4 antibody.
Liu J; Xu L; Chen ZL; Li M; Yi H; Peng FH
Bosn J Basic Med Sci; 2018 Feb; 18(1):35-42. PubMed ID: 29144890
[TBL] [Abstract][Full Text] [Related]
15. Role of C5 inhibitors in neuromyelitis optica spectrum disorders with seropositive anti-aquaporin-4 antibody: A systematic review and meta-analysis.
Makkawi S; Salamatullah HK; Alkhiri A; Faidah DE; Afif LM; Bukhari JI; Abulaban A; Al Malik Y; Levy M
Mult Scler Relat Disord; 2024 May; 85():105524. PubMed ID: 38479045
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of recurrence in area postrema-onset NMO spectrum disorder - a retrospective cohort study.
Zhang X; Wu J; Lin J; Lin S; Lin A
BMC Neurol; 2024 May; 24(1):165. PubMed ID: 38773402
[TBL] [Abstract][Full Text] [Related]
17. Stage-dependent immunity orchestrates AQP4 antibody-guided NMOSD pathology: a role for netting neutrophils with resident memory T cells in situ.
Nakajima A; Yanagimura F; Saji E; Shimizu H; Toyoshima Y; Yanagawa K; Arakawa M; Hokari M; Yokoseki A; Wakasugi T; Okamoto K; Takebayashi H; Fujii C; Itoh K; Takei YI; Ohara S; Yamada M; Takahashi H; Nishizawa M; Igarashi H; Kakita A; Onodera O; Kawachi I
Acta Neuropathol; 2024 Apr; 147(1):76. PubMed ID: 38658413
[TBL] [Abstract][Full Text] [Related]
18. Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis.
Hua T; Fan H; Duan Y; Tian D; Chen Z; Xu X; Bai Y; Li Y; Zhang N; Sun J; Li H; Li Y; Li Y; Zeng C; Han X; Zhou F; Huang M; Xu S; Jin Y; Li H; Zhuo Z; Zhang X; Liu Y
J Neurol; 2024 Jun; 271(6):3595-3609. PubMed ID: 38558149
[TBL] [Abstract][Full Text] [Related]
19. Risks and outcomes of pregnancy in neuromyelitis optica spectrum disorder: A comprehensive review.
Siriratnam P; Huda S; Butzkueven H; van der Walt A; Jokubaitis V; Monif M
Autoimmun Rev; 2024 Feb; 23(2):103499. PubMed ID: 38061621
[TBL] [Abstract][Full Text] [Related]
20. An Aberrant Case of Neuromyelitis Optica Spectrum Disorder With a Review of Literature.
Dhok A; Ratnaparkhi C; Kumar S; Manhas SD; Umredkar A
Cureus; 2024 May; 16(5):e59765. PubMed ID: 38846197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
